Joseph Ingrassia, MD
Interventional Cardiology · Hartford, CTNPI 1336432517
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (40.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Inquis Medical, Inc. at 51.3% of the total. 2025 is the largest year on record at $10,224, more than ten times the $563 reported in 2019.
Across 170 payments — averaging $96.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inquis Medical, Inc.$8K
- Medtronic$2K
- Boston Scientific$1K
- Cardiovascular Systems Inc.$895
- Terumo Medical Corporation$615
- Abbott$565
- plus $3K from 26 others
Across 21 payments — averaging $17,642 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$370K
What the payments were for
- Consulting fees$6,60040%
- Speaking & faculty fees$1,0356%
- Travel & lodging$2,32314%
- Food & beverage$6,34139%
- Education$1411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inquis Medical, Inc. | 6 | $8,433 |
| Medtronic | 40 | $1,665 |
| Boston Scientific | 3 | $1,071 |
| Cardiovascular Systems Inc. | 20 | $895 |
| Terumo Medical Corporation | 3 | $615 |
| Abbott | 13 | $565 |
| AstraZeneca | 14 | $493 |
| Johnson & Johnson | 11 | $424 |
| Inari Medical, Inc. | 7 | $298 |
| Penumbra, Inc. | 2 | $285 |
| Shockwave Medical, Inc | 6 | $258 |
| Chiesi USA, Inc. | 6 | $165 |
| Abiomed | 3 | $149 |
| Cardinal Health 200 LLC | 4 | $146 |
| Amgen | 2 | $145 |
| Bard Peripheral Vascular, Inc. | 2 | $113 |
| Philips North America LLC | 2 | $103 |
| Lilly USA, LLC | 2 | $93 |
| BD | 1 | $77 |
| E.r. Squibb & Sons, L.L.C. | 3 | $71 |
| Edwards Lifesciences | 3 | $63 |
| Amarin Pharma, Inc. | 3 | $59 |
| AbbVie | 3 | $55 |
| GSK | 2 | $33 |
| Acist Medical Systems, Inc. | 1 | $26 |
| Novartis | 2 | $25 |
| Heartflow, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| Opsens Inc. | 1 | $18 |
| GE HealthCare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Aventus$8,407
- EKOSONIC$1,035
- VenaSeal$416
- GlideWire$350
- Navicross$250
- XARELTO$235
- Diamondback Peripheral$169
- Diamondback Coronary$169
- RUBY Coil$144
- CARDIOMEMS$144
- Indigo$141
- SYMPLICITY G3$133
- Coronary Orbital Atherectomy System$132
- RESOLUTE ONYX$117
- BRILINTA$112
- Impella$102
How this compares
$16,440 in reported general payments places this provider in the 80th percentile of 73 interventional cardiology providers in Connecticut.
See all interventional cardiology providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 14 | $17,103 |
| Cilostazol | 19 | $931 |
| Rosuvastatin Calcium | 48 | $623 |
| ClopidogrelClopidogrel Bisulfate | 39 | $485 |
| Lisinopril | 12 | $85 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $424 | $17,10314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 73 interventional cardiology providers in Connecticut.
Other interventional cardiology in Hartford
- Craig ThompsonHartford$222K
- Abdul QaziHartford$38K
- Sarfaraz MemonHartford$30K
- Boskey PatelHartford$20K
- Talhat AzemiHartford$12K
- Bryan PiccirilloHartford$12K
- Immad SadiqHartford$9K
- Asad RizviHartford$5K
- Daniel FramHartford$3K
- Arslan MasoodHartford$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.